Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Eli Lilly (LLY) stock is in focus as its popular GLP-1 med Mounjaro hits main goals in a Phase 3 trial for children and ...

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling ...

Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks ...

Eli Lilly and Company saw its stock price ascend on Tuesday, buoyed by promising reports about orforglipron, its ...

Nvov Nordisk stock rose after a study showed Ozempic reduced the risk of heart attack, stroke and death by 23% compared with ...